Currency In USD
| Previous Close | 4.56 |
| Open | 4.68 |
| Day High | 4.68 |
| Day Low | 4.51 |
| 52-Week High | 41.8 |
| 52-Week Low | 3.25 |
| Volume | 10,556 |
| Average Volume | 549,760 |
| Market Cap | 9.14M |
| PE | -0.15 |
| EPS | -29.56 |
| Moving Average 50 Days | 5.65 |
| Moving Average 200 Days | 7.02 |
| Change | -0.01 |
Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome
GlobeNewswire Inc.
Mar 11, 2026 12:30 PM GMT
— Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need — — QRX003 lotion (4%) currently being evaluated in two late-stage whole-body clinical tri
NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome
GlobeNewswire Inc.
Feb 26, 2026 1:30 PM GMT
Videos on the NETHERTON NOW website have been viewed 2 million times with 24 million impressions Patients, families, and clinicians share the reality of living with Netherton Syndrome, a rare genetic skin disease with no approved treatment, and
Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome
GlobeNewswire Inc.
Jan 27, 2026 1:30 PM GMT
Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status Quoin Initiating the Establishment of a Japanese Subsidiary to Facilitate Self-Commercialization of QRX003 in Japan, if App